9results about How to "Reduce moisture absorption performance" patented technology

The application provides a high-refraction cycloolefin copolymer and a preparation method thereof, and has a structure of formula I. The cycloolefin copolymer can obtain a cycloolefin copolymer resin with high thermal stability due to high steric hindrance of the cycloolefin monomer. The refractive index of the cycloolefin copolymer resin is greatly improved due to R3 and R4 on the cycloolefin monomer, and is first broken through to above 1.70, while maintaining high light transmittance of 91.0-96.0%, extremely low water absorption (<0.01%), and a glass transition temperature of 219 DEG C. The application prepares the cycloolefin copolymer resin with high activity, adjustable molecular weight and glass transition temperature by adjusting the reaction conditions. The copolymer resin has high refractive index, high light transmittance, heat resistance, low birefringence and moisture absorption, excellent fluidity, moldability and dimensional stability.

The present application relates to a solid form of an indole compound, a preparation method therefor and a use thereof. Specifically, the present application relates to a solid form of a compound of Formula (1), a method of preparing same, a pharmaceutical composition comprising same, and a use thereof in treating a disease.

Provided are a solid form of a Rho-associated protein kinase inhibitor (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone or a solvate thereof, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and a use of the solid form as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.

The invention provides light lyocell cotton denim with low fibrillation and antibacterial and anti-mosquito functions and a preparation method of the light lyocell cotton denim, and relates to the technical field of functional finishing of textiles. The preparation method of the light lyocell cotton denim with low fibrillation and antibacterial and anti-mosquito functions comprises the five steps of fabric pretreatment, finishing liquid preparation, double-section padding, third-order curing and after-finishing. Through the synergistic effect of gradient crosslinking and natural antibacterial and anti-mosquito components, the fabric is endowed with lasting antibacterial and anti-mosquito functions while fibrillation of lyocell fibers is effectively inhibited, the technical problem that in a traditional finishing method, it is difficult to consider both fibrillation and functionality at the same time is solved, and the antibacterial and anti-mosquito effects of the fabric are improved. And the prepared fabric has excellent fibrillating resistance, lasting antibacterial and anti-mosquito effects and good softness and comfort.

The invention discloses a bio-based core-shell structure flame retardant and an application thereof in a bio-based plate. According to the invention, a phosphorus-carbon synergistic flame-retardant core-shell structure flame retardant is developed by taking a phosphorus-containing halogen-free flame retardant as a core and carrying out free radical copolymerization reaction on a furfuryl alcohol (FA) derivative containing phosphorus in different oxidation states and bismaleimide (BMI) with a charring function to form a cross-linked flame-retardant macromolecular shell layer. The core-shell flame retardant is proportionally mixed with crushed materials of a biological base material and an adhesive, and the mixture is subjected to hot press molding to obtain the flame-retardant biological base material. The flame retardant provided by the invention not only can endow a biological base material with good flame retardance and mechanical properties, but also can solve the problem of long-term durability of the biological base material.

The invention provides siloxane-based liquid cooling oil and a preparation method thereof, and the preparation method comprises the following steps: placing a cyclic siloxane monomer in an inert atmosphere, adding an acid catalyst and a base catalyst, and carrying out an acid-base dual-catalysis ring-opening polymerization reaction to obtain methyl-phenyl copolymerized siloxane, carrying out high-temperature distillation on the methyl-phenyl copolymerized siloxane to obtain siloxane-based liquid-cooled oil carrier liquid; the method comprises the following steps: adding a tertiary amine catalyst and deionized water into an organic alkoxy silane monomer and a fluoropropyl substituted alkoxy silane monomer, and carrying out a hydrolytic condensation reaction to obtain a siloxane precursor which comprises a liquid micro-network precursor and a hydrophobic chain segment precursor; the siloxane-based carrier liquid and the siloxane precursor are stirred and mixed according to a preset mass ratio, vacuum defoaming is performed after functional auxiliaries are added, the siloxane-based liquid cooling oil is obtained, and the functional auxiliaries comprise a polyether grafted dispersing agent and a low-molecular silicone oil rheology modifier. The defects that traditional liquid cooling oil is prone to blistering and dielectric gliding are effectively overcome.

The present application provides a crystalline form of tolebrutinib, an amorphous form, and a method of preparation thereof and a use thereof, and the crystalline form of tolebrutinib provided in the present application has at least one of the following advantages: good stability, low moisture attraction, uniform particle size distribution, solubility meeting the requirements for medicinal use, stable storage, avoiding phase transformation of the drug in the process of development and in storage, and a reliable method for the preparation thereof, which has a great development value. The amorphous form of tolebrutinib provided in this application, while possessing better solubility than that of tolebrutinib in the crystalline state, still possesses good stability of placement and acceptable hygroscopicity, and has high medicinal value.

This application relates to the chemical field of medicine, specifically to tolebrutinib salts and their crystal forms, their preparation methods, their pharmaceutical compositions, and their uses. Tolebrutinib hydrochloride and its crystal form provided in this application have at least one advantage: good stability, low hygroscopicity, solubility meeting medicinal requirements, uniform particle size distribution, good morphology, good flowability, good compressibility, good crystallinity, good storage stability, avoiding phase transformation during drug development and storage, simple and reliable preparation method, and great development value. The tolebrutinib maleate and its crystal form of this application have at least one advantage: good stability, uniform particle size distribution, good flowability, solubility meeting pharmaceutical requirements, good storage stability, avoiding phase transformation during drug development and storage, and simple and reliable preparation method.

This application relates to the field of chemistry of drugs. It relates to a lazertinib monomethanesulfonate hydrate crystal form, its preparation method thereof and uses. The crystal form of lazertinib monomethanesulfonate hydrate provided in this application has at least one of the following advantageous properties: good stability, high solubility, good dissolution, low hygroscopicity, uniform particle size distribution, favorable morphology, good flowability, and high crystallinity. These characteristics contribute to stable storage, preventing degradation, increased impurities, changes in appearance, and crystallization during development and storage. The preparation method is simple and reliable, offering significant development value.